Andrew J. Armstrong, MD, ScM, FACP, presented “ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients” for the Grand Rounds in Urology audience in December 2019.
How to cite: Armstrong, Andrew J. “ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients” December, 2019. Accessed Dec 2024. https://grandroundsinurology.com/enzamet-and-arches-trials-provides-evidence-of-enzalutamide-as-life-prolonging-therapy-in-mhspc-patients/
ENZAMET & ARCHES Trials Provides Evidence of Enzalutamide as Life-Prolonging Therapy in mHSPC Patients – Summary:
Andrew J. Armstrong, MD, ScM, FACP, Professor and Director of Research at Duke Cancer Institute Center for Prostate and Urologic Cancers and lead author of the ARCHES study, gives an overview of the ARCHES trial and related ENZAMET trial, which demonstrated showed the use of enzalutamide improved survival and reduced disease progression in men with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Armstrong compares enzalutamide to first-generation androgen receptor inhibitors such as flutamide and bicalutamide, discusses the strong results supporting enzalutamide in both trials, and the implications for future mHSPC treatment using androgen deprivation.
ABOUT THE AUTHOR
Andrew J. Armstrong, MD, ScM, FACP, is a tenured Professor of Medicine, Surgery, Pharmacology, and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally-recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer and received his medical degree at the University of Virginia. He completed medicine residency training at the University of Pennsylvania, and fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health. He joined Duke’s faculty in 2006.
As a clinical and translational investigator, he is focused on experimental therapeutics for patients with advanced genitourinary malignancies. He is funded by the US Department of Defense, PCF/Movember, the NIH, and the American Cancer Society for his work on circulating tumor cell biology and epithelial plasticity. He led the development of enzalutamide and its FDA approval for men with metastatic prostate cancer. He was a Prostate Cancer Foundation, AACR, and ASCO Young Investigator Award recipient. He co-chaired Prostate Cancer Working Group 3, and has been a leading writing member of the NCCN Prostate Cancer Panel since 2012 for national clinical guidelines on the treatment of men with prostate cancer.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and he is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer, including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 160 peer-reviewed publications, as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic.
